Treatment for Lung Cancer in Adults over Age 70
Study name: Older Non-Small Lung Cancer Patients (>/= 70 Years of Age) Treated with First-Line MK-3475 (Pembrolizumab) +/- Chemotherapy (Oncologist’s/Patient’s Choice)
Description: Researchers at the WL Nugent Cancer Center are conducting a clinical trial that involves adults age 70 and over who have non-small cell lung cancer that has spread to other parts of the body. Patients will receive immunotherapy medication (pembrolizumab), which uses your body’s immune system to fight cancer. The goal of the study is to better understand the effectiveness of immunotherapy and possible side-effects in older adults.
- Group 1: Receive immunotherapy medication (pembrolizumab) alone.
- Group 2: Receive immunotherapy medication (pembrolizumab) combined with chemotherapy medications (carboplatin and pemetrexed).
Who can participate?
This study is open to men and women age 70 and over who have been diagnosed with advanced Stage 4 non-small cell lung cancer.
What to expect
- You will meet with your doctor to discuss what is involved in the study and the possible benefits and risks. If you and your doctor agree this clinical trial is right for you, you will be asked to sign a consent form.
- You and your doctor will decide which of the above treatment groups is appropriate for you.
- You will periodically complete questionnaires about your condition, side-effects from treatment, etc.
- Blood samples may be collected before, during, and after treatment for study analysis.
Please talk with your doctor about whether this clinical trial is right for you.